4.4 Review

Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy

期刊

ANTI-CANCER DRUGS
卷 17, 期 1, 页码 13-20

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.cad.0000185180.72604.ac

关键词

angiogenesis; cancer; cell motility; Grb2; growth factor receptor-bound 2; metastasis

资金

  1. Intramural NIH HHS Funding Source: Medline
  2. NATIONAL CANCER INSTITUTE [Z01SC006659, ZIABC006198, Z01BC006198] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Growth factor receptor-bound 2 (Grb2) is a ubiquitously expressed adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway. As such, it has been implicated in the oncogenesis of several important human malignancies. In addition to this function, research over the last decade has revealed other fundamental roles for Grb2 in cell motility and angiogenesis-processes that also contribute to tumor growth, invasiveness and metastasis. This functional profile makes Grb2 a high priority target for anti-cancer drug development. Knowledge of Grb2 protein structure, its component Src homology domains and their respective structure-function relationships has facilitated the rapid development of sophisticated drug candidates that can penetrate cells, bind Grb2 with high affinity and potently antagonize Grb2 signaling. These novel compounds offer considerable promise in our growing arsenal of rationally designed anti-cancer therapeutics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据